Brief: Transcode Therapeutics Receives Equity Investment From White Lion Capital
14/04/2023 12:14
April 14 (Reuters) - Transcode Therapeutics Inc
RNAZ.O :
* TRANSCODE THERAPEUTICS ANNOUNCES EQUITY INVESTMENT FROM
WHITE
LION CAPITAL TO HELP FUND DEVELOPMENT OF TTX-MC138 FOR TREATMENT
OF GLIOBLASTOMAS
* TRANSCODE THERAPEUTICS INC - DEAL PROVIDES CO WITH RIGHT
TO SELL
WHITE LION CAPITAL UP TO ABOUT $1.08 MILLION OF ITS COMMON STOCK
UNTIL MAY 31
Source text for Eikon: ID:nGNX3ZpznF
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors